Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab

Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients

-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.

Inclusion Criteria:

• Histologically confirmed colorectal adenocarcinoma;
• Measurable metastatic disease according to RECIST criteria;
• Patients receiving BV plus FOLFIRI as first-line treatment;
• Written informed consent;
• Availability of blood samples for genetic analysis.-

Exclusion Criteria: